Table 3.xls (21.5 kB)

Results of key secondary endpoints from identified trials among ARV-naive patients.

Name: Results of key secondary endpoints from identified trials among ARV-naive patients.
Published: 2016-02-05T18:11:59+00:00
License: https://creativecommons.org/licenses/by/4.0/
Keywords: toxicity reduction advantages, TOXNET, International Pharmaceutical Abstracts, virologic efficacy outcomes, Virologically Suppressed Patients ObjectiveWe, integrase inhibitor raltegravir, transcriptase inhibitor lamivudine, HIV infection.MethodsA search, bone mineral density, Derwent Drug File, Dual Therapy Treatment Strategies, expert review committee, therapy regimens, ARV

dataset

posted on 2016-02-05, 18:11 authored by Jean-Guy Baril, Jonathan B. Angel, M. John Gill, Joseph Gathe, Pedro Cahn, Jean van Wyk, Sharon Walmsley

Results of key secondary endpoints from identified trials among ARV-naive patients.

History

Usage metrics

Categories

Keywords

Licence

Exports